A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. (Q39130806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

meta-analysis

0 references

title

A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Peter J Morris

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Simon R Knight

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

publication date

24 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

published in

Transplantation Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

87-95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes

2 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Antibody-mediated rejection following renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Targeting B cells and antibody in transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Current approaches to treatment of antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Effective B cell depletion with rituximab in the treatment of autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

A systematic review of the use of rituximab as induction therapy in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

A systematic review of the use of rituximab for desensitization in renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

National conference to assess antibody-mediated rejection in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Overcoming a positive crossmatch in living-donor kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Rituximab therapy for acute humoral rejection after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

New treatments for acute humoral rejection of kidney allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN')

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

C4d-positive chronic rejection: a frequent entity with a poor outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Identifying specific causes of kidney allograft loss.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Treatment of antibody-mediated rejection in renal transplant patients: a clinical practice survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Evaluating non-randomised intervention studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Impact of rituximab therapy for treatment of acute humoral rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Low- versus high-dose rituximab for antibody-mediated rejection after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2017.01.002

10.1016/J.TRRE.2017.01.002

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28187998%20AND%20SRC:MED&resulttype=core&format=json